An investor has filed a lawsuit in California State Court challenging Varian's proposed $1.5 billion sale to Agilent Technologies.

Under the terms of the proposed acquisition announced last week, Agilent will pay $52 for each share of Varian stock, a 35 percent premium over the closing price of Varian's stock on the trading day before the proposal was announced [see PM 07/30/09].

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.